KLF4 and breast carcinoma: MiR-484, by targeting KLF4, increases the sensitivity of tamoxifen-resistant breast cancer cells and is commonly involved in critical signaling pathways related to breast cancer progression, indicating its potential as a diagnostic biomarker because of its high levels in the plasma and serum of patients with breast cancer 45-47.